ReceptorBio Company Profile, Contacts & Intelligence

ReceptorBio Overview

ReceptorBio is an early-stage biopharmaceutical company that is developing orally active pharmaceuticals for the treatment of insulin resistance, type 2 diabetes mellitus (T2D), and the ‘Metabolic Syndrome’, all of which are linked to a markedly increased risk of cardiovascular disease and other disorders. The Company’s initial focus will be on the clinical development of its lead compound, RB101, a late stage pre-clinical compound that activates the tyrosine kinase domain of the insulin receptor (IR), a recognized drug target for T2D. Activation of the IR is required to mediate insulin’s physiological effects on the control of blood glucose and other processes. Currently, there are no FDA-approved drugs with this mechanism of action. ReceptorBio believes its novel agent is first in class, with a mechanism of action that is compatible for use both as a single agent and in combination with existing drugs for T2D.

Headquarters

Redwood City, California, United States

Website

www.receptorbiohq.com

Industry

Pharmaceutical Manufacturing

Founded

2008

NAICS

Pharmaceutical and Medicine Manufacturing, Medicinal and Botanical Manufacturing

Compare Similar Companies to ReceptorBio

Explore companies in related markets and compare their industry and employee estimates.